NexgenRx Inc. (TSXV:NXG)

NexgenRx Cash Flow Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	1.44	0.61	-0.33	-0.02	4.02	2.12
Depreciation & Amortization	-0.39	0.3	0.27	1.41	1.33	0.94
Other Amortization	1.66	0.97	1.04	-	-	0.03
Loss (Gain) From Sale of Assets	-0.04	-	-	0.22	-	-
Stock-Based Compensation	0.01	0.02	0.04	0.06	0.1	0.08
Other Operating Activities	0.81	0.39	0.04	-0.02	-2.06	-0.22
Change in Accounts Receivable	0.15	-0.1	-0.32	0.07	-0.12	0.01
Change in Accounts Payable	-0.45	-0.68	0.26	-0.49	0.54	-0.28
Change in Other Net Operating Assets	-0.39	-0.36	0.29	-0.16	0.01	-0.01
Operating Cash Flow	2.81	1.15	1.28	1.07	3.82	2.65
Operating Cash Flow Growth	176.19%	-9.95%	19.82%	-72.13%	44.16%	153.70%
Capital Expenditures	-0.32	-0.09	-0.08	-0.39	-0.13	-0.12
Sale (Purchase) of Intangibles	-0.19	-0.23	-0.17	-0.12	-1.24	-0.96
Investment in Securities	-0.2	-0.18	-	-	-	-
Investing Cash Flow	-0.72	-0.5	-0.25	-0.51	-1.37	-1.08
Long-Term Debt Repaid	-	-0.1	-0.08	-0.21	-0.81	-1.4
Total Debt Repaid	-0.13	-0.1	-0.08	-0.21	-0.81	-1.4
Net Debt Issued (Repaid)	-0.13	-0.1	-0.08	-0.21	-0.81	-1.4
Issuance of Common Stock	-	0.19	0.06	-	-	-
Preferred Dividends Paid	-0.2	-0.2	-0.2	-0.2	-0.13	-
Common Dividends Paid	-1.07	-0.71	-0.7	-0.7	-	-
Dividends Paid	-1.26	-0.91	-0.9	-0.9	-0.13	-
Financing Cash Flow	-1.39	-0.82	-0.92	-1.11	-0.94	-1.3
Net Cash Flow	0.7	-0.17	0.11	-0.55	1.52	0.27
Free Cash Flow	2.48	1.06	1.2	0.68	3.7	2.53
Free Cash Flow Growth	161.95%	-11.31%	77.23%	-81.69%	46.03%	154.52%
Free Cash Flow Margin	14.00%	6.46%	8.67%	5.30%	31.23%	23.95%
Free Cash Flow Per Share	0.03	0.01	0.02	0.01	0.05	0.03
Levered Free Cash Flow	1.62	0.5	1.32	0.55	1.83	0.58
Unlevered Free Cash Flow	1.62	0.52	1.33	0.56	1.87	0.68
Change in Working Capital	-0.69	-1.14	0.23	-0.58	0.43	-0.29

Source: S&P Global Market Intelligence. Standard template. Financial Sources.